Abstract
Here, we recount the story of a remarkable young girl who demonstrated extraordinary courage and resilience while confronting significant health challenges over the span of 23 years. Her journey is a testament to her determination to survive and thrive despite overwhelming obstacles. We detail the investigative efforts aimed at associating her clinical symptoms with a specific membrane transporter: the Na-K-2Cl cotransporter-1 (NKCC1), which this laboratory has dedicated more than three decades to studying. The work summarized here covers experiments using patient-derived cells, cells engineered to express wild-type or mutant cotransporter, and genetically modified mice carrying this patient-specific alteration. It is illuminated by reports of other rare human deleterious mutations, and work done by us and others using NKCC1 knockout mouse models. During our studies, we uncovered details regarding the trafficking of NKCC1, shedding light on how the protein is transported and positioned to carry out its function in epithelial cells. Furthermore, our findings revealed that NKCC1 may play a role in energy metabolism, suggesting that its activity influences metabolic processes within affected tissues. Our investigations also underscored the involvement of NKCC1 in the development of the nervous system. In addition, we discuss the evidence found that intestinal dysfunction is linked to NKCC1 abnormalities and evidence showing an established link between the cotransporter and epithelial cell-mediated inflammation. This patient's story stands as a testament to perseverance and the importance of scientific inquiry in understanding rare genetic disorders.